Officer Jamil Khurram files intent to sell additional shares after recent significant sales
GALT has more than doubled off its 52-week low of $0.94.
Summary
An officer of Galectin Therapeutics has filed a Form 144 to sell additional shares, following approximately $799,099 in sales over the last three months.
Key Events · Ownership and Investor Activity · GALT
-
Officer's Intent to Sell
Officer Jamil Khurram filed a Form 144 indicating an intent to sell 8,125 shares of common stock, valued at approximately $33,313.
-
Recent Significant Sales
The filing also disclosed that the same officer has sold 140,559 shares for gross proceeds of approximately $799,099 over the past three months.
-
Cumulative Insider Selling
The combined recent and proposed sales by this officer total over $832,000, representing a notable reduction in insider holdings.
Analysis · GALT · Life Sciences
This Form 144 filing indicates that Officer Jamil Khurram intends to sell 8,125 shares of common stock. More significantly, the filing also discloses that Mr. Khurram has already sold 140,559 shares for gross proceeds of approximately $799,099 over the past three months. This pattern of consistent selling by an officer, totaling over $832,000 in recent and proposed sales, could be interpreted negatively by investors as it suggests a reduction in insider ownership and conviction.
At the time of this filing, GALT was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $268.2M. The 52-week trading range was $0.94 to $7.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.